Pacific Biosciences Of California (PACB) Receivables (2010 - 2026)

Pacific Biosciences Of California has reported Receivables for 17 years, with the latest figure at $31.1 million in Q2 2026.

• On a quarterly basis, Receivables fell 3.57% year-over-year to $31.1 million in Q2 2026; TTM through Jun 2026 was $31.1 million, a 3.57% decrease from a year earlier, with the FY2025 full-year figure at $35.4 million, up 28.79% from the prior year.
• Receivables was $31.1 million for Q2 2026 at Pacific Biosciences Of California, up from $29.4 million in the prior quarter.
• The five-year high for Receivables was $36.6 million in Q4 2023, with the low at $18.8 million in Q4 2022.
• Average Receivables over 5 years is $29.3 million, with a median of $30.0 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Receivables surged 115.81% in 2022, then dropped 24.83% in 2024.
• Over 5 years, Receivables stood at $18.8 million in 2022, then soared by 94.91% to $36.6 million in 2023, then dropped by 24.83% to $27.5 million in 2024, then increased by 28.79% to $35.4 million in 2025, then fell by 12.25% to $31.1 million in 2026.
• The last three Receivables figures came in at $31.1 million (Q2 2026), $29.4 million (Q1 2026), and $35.4 million (Q4 2025), per Business Quant data.